EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis

Yiran Sun, Yangang Zhou, Tong Peng, Yuhang Huang, Hao Lu, Xiran Ying, Mingsheng Kang, Hao Jiang, Jingying Wang, Jiayao Zheng, Chenyu Zeng, Wanting Liu und 3 weitere

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2024.113696 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yiran Sun und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Chengdu Medical College, Chengdu 610500, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 167 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Shanxi Provincial Science and Technology Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a prevalent inflammatory skin disorder characterized by its chronic, persistent, and recurrent nature. The pathophysiology of this condition is complex, involving various factors including cell-mediated immune responses, compromised skin barrier function, and alterations in hypersensitivity reactions. These components synergistically contribute to the perpetuation of the bothersome "itch-scratch-itch" cycle. Recent research has highlighted the significant role of the NLRP3 inflammasome in the development of AD and other inflammatory conditions. Current research indicates that the NLRP3 inflammasome plays a pivotal role in both the acute and chronic phases of AD by modulating the Th2/Th1 immune deviation. Moreover, the pharmacological suppression of NLRP3 has shown promising results in mitigating the pathological aspects of AD. This review outlines potential drug development strategies that target the NLRP3 inflammasome as a therapeutic approach for AD and the challenges faced in this endeavor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesHumansAnimalsTh2 Cells

Stichwörter der Autor:innen

Atopic dermatitisDrug discoveryNLRP3 inflammasomeNLRP3 inhibitorType 2 inflammation

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNLRP3 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
  • School of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China.
  • Department of R&D, Keystonecare Technology (Chengdu) Co., Ltd, Chengdu 610094, China.
  • School of Biosciences and Technology, Key Laboratory of Target Discovery and Protein Drug Development in Major Diseases at Chengdu Medical College of Sichuan Province, Chengdu Medical College, Chengdu 610500, China.
  • College of Life Sciences, Sichuan Normal University, Chengdu 610101, China.
  • Department of Dermatology and Venereology, Nanbu County People's Hospital, Nanchong 637399, China.

Förderung

  • China Postdoctoral Science Foundation
  • Shanxi Provincial Science and Technology Department

Zitieren

APA

Sun, Y., Zhou, Y., Peng, T., Huang, Y., Lu, H., Ying, X., Kang, M., Jiang, H., Wang, J., Zheng, J., Zeng, C., Liu, W., Zhang, X., Ai, L., & Peng, Q. (2025). Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113696

Vancouver

Sun Y, Zhou Y, Peng T, Huang Y, Lu H, Ying X, et al. Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113696

BibTeX
@article{Sun2025,
  author = {Sun, Yiran and Zhou, Yangang and Peng, Tong and Huang, Yuhang and Lu, Hao and Ying, Xiran and Kang, Mingsheng and Jiang, Hao and Wang, Jingying and Zheng, Jiayao and Zeng, Chenyu and Liu, Wanting and Zhang, Xiaoyu and Ai, Lin and Peng, Quekun},
  title = {Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2024.113696}
}
Kostenlos starten →